A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5729-5737

  McArthur, Heather L ^a   Diab, Adi ^b   Page, David B ^a   Yuan, Jianda ^a   Solomon, Stephen B ^a   Sacchini, Virgilio ^a   Comstock, Christopher ^a   Durack, Jeremy C ^a   Maybody, Majid ^a   Sung, Janice ^a   Ginsberg, Arielle ^a   Wong, Phillip ^a   Barlas, Afsar ^a   Dong, Zhiwan ^a   Zhao, Chunjun ^a   Blum, Brian ^a   Patil, Sujata ^a   Neville, Deirdre ^a   Comen, Elizabeth A ^a   Morris, Elizabeth A ^a   Kotin, Alan ^a   Brogi, Edi ^a   Wen, Y Hannah ^a   Morrow, Monica ^a   Lacouture, Mario E ^a   Sharma, Padmanee ^b   Allison, James P ^b   Hudis, Clifford A ^a   Wolchok, Jedd D ^a   Norton, Larry ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; KI 67 ANTIGEN; TUMOR ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ADVERSE OUTCOME; AGED; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOABLATION; CYTOKINE RESPONSE; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MASTECTOMY; OUTCOME ASSESSMENT; PILOT STUDY; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; TREATMENT PLANNING; BREAST TUMOR; CRYOSURGERY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; REGULATORY T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CRYOSURGERY; FEMALE; HUMANS; IPILIMUMAB; MIDDLE AGED; PILOT PROJECTS; PREOPERATIVE CARE; RECEPTOR, ERBB-2; T-LYMPHOCYTES, REGULATORY;

EID: 85006325446     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0190     Document Type: Article

References (37)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
4. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010;16:3485-94.
5. Emens LA.Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). AACR Annual Meeting. Philadelphia, PA; April 20, 2015.
6. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34:2460-7.
7. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science; 348:69-74.
8. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann Oncol 2015;26:259-71.
9. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD- L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361-70.
10. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
11. Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 2005; 90:97-104.
12. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012;72:430-9.
13. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24:2174-80.
14. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522-30.
15. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65.
16. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph- Pietras D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+T-cell response. Sci Transl Med 2014;6:254ra128.
17. Yuan J, PageDB, KuGY, Li Y,MuZ, AriyanC, et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 2010;10:1.
18. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16:2861-71.
19. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701-21.
20. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009;21:1303-9.
21. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccinewith booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014;25:1735-42.
22. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, et al. ICOS co- stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97-101.
23. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014;211:715-25.
24. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, et al. Increased frequency of ICOS+CD4 T cells as a pharmacodynamic biomarker for anti- CTLA-4 therapy. Cancer Immunol Res 2013;1:229-34.
25. Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013;62: 1021-8.
26. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc- dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti- CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710.
27. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-10.
28. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008;105:14987-92.
29. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
30. van Rooij N, van BuurenMM, PhilipsD, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31: e439-42.
31. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials:ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959-66.
32. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014;25:1544-50.
33. Tian T, Ruan M, Yang W, Shui R. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget 2016[Epub ahead of print].
34. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014;25:611-8.
35. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860-7.
36. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010 ;28:105-13.
37. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.